Gaetano Bergamaschi et al. indicated that infliximab could increase the growth of erythroid progenitors from the peripheral blood of patients with active disease to improve anemia (17), while Shu et al. discovered that infliximab blocked the caspase-3/8 and NF-κB pathways and inhibited the expression of hepcidin, a key regulator of iron metabolism, to mediate the occurrence of anemia in IBD (24). Here, NFKB1 is linked to inflammatory bowel disease.